Abstract:Glaucoma, an age-related neurodegenerative disease, is characterized by the death of retinal ganglion cells (RGCs) and the corresponding loss of visual fields. This disease is the leading cause of irreversible blindness worldwide, making early diagnosis and effective treatment paramount. The pathophysiology of primary open-angle glaucoma (POAG), the most common form of the disease, remains poorly understood. Current available treatments, which target elevated intraocular pressure (IOP), are not effective at slowing disease progression in approximately 30% of patients. There is a great need to identify and study treatment options that target other disease mechanisms and aid in neuroprotection for POAG. Increasingly, the role of mitochondrial injury in the development of POAG has become an emphasized area of research interest. Disruption in the function of mitochondria has been linked to problems with neurodevelopment and systemic diseases. Recent studies have shown an association between RGC death and damage to the cells' mitochondria. In particular, oxidative stress and disrupted oxidative phosphorylation dynamics have been linked to increased susceptibility of RGC mitochondria to secondary mechanical injury. Several mitochondria-targeted treatments for POAG have been suggested, including physical exercise, diet and nutrition, antioxidant supplementation, stem cell therapy, hypoxia exposure, gene therapy, mitochondrial transplantation, and light therapy. Studies have shown that mitochondrial therapeutics may have the potential to slow the progression of POAG by protecting against mitochondrial decline associated with age, genetic susceptibility, and other pathology. Further, these therapeutics may potentially target already present neuronal damage and symptom manifestations. In this review, the authors outline potential mitochondria-targeted treatment strategies and discuss their utility for use in POAG.

Glucagon-Like Peptide 1 Receptor Agonists - Potential Game Changers in the Treatment of Glaucoma?

Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma

Therapeutic strategies for glaucoma and optic neuropathies

Advances in Neuroprotection in Glaucoma: Pharmacological Strategies and Emerging Technologies

Prostaglandin FP receptor agonists in the treatment of glaucoma and ocular hypertension: a literature review

Glial cells as a promising therapeutic target of glaucoma: beyond the IOP

Cell-Based Therapies for Glaucoma

Investigational drugs targeting prostaglandin receptors for the treatment of glaucoma

Comprehensive review of glucagon-like peptide 1 receptor agonist treatment on the risk of cardiovascular outcomes and retinopathy as diabetic complications.

Glaucomatous optic neuropathy treatment options: the promise of novel therapeutics, techniques and tools to help preserve vision

Protection of retinal ganglion cells in glaucoma: Current status and future

Gene therapy for glaucoma: Targeting key mechanisms

Autophagy modulators as potential neuroprotective drugs in glaucoma

GLP-1 Receptor Agonist NLY01 Reduces Retinal Inflammation and Neuron Death Secondary to Ocular Hypertension

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy

To the Brain and Beyond: Neurological Implications of Glucagon-Like Peptide-1 Receptor Agonists

The potential for mitochondrial therapeutics in the treatment of primary open-angle glaucoma: a review

The Role of Neurotrophins and Mimetics in the Treatment of Ocular Diseases

Glaucoma: the retina and beyond

Neuroprotection in Glaucoma: Present and Future.

Gene therapy strategies for glaucoma from IOP reduction to retinal neuroprotection: progress towards non-viral systems